Literature DB >> 19198856

Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance?

Petros D Grivas1, Vassiliki Tzelepi, Georgia Sotiropoulou-Bonikou, Zinovia Kefalopoulou, Athanasios G Papavassiliou, Haralabos Kalofonos.   

Abstract

PURPOSE: Estrogen receptor beta (ER beta) is abundantly expressed in colorectal tissue, but its role in colorectal carcinogenesis remains elusive. Estrogen receptor coregulators, amplified in breast cancer 1 (AIB1) and transcription intermediary factor 2 (TIF2), have been well-characterized, but their expression in colorectal carcinomas has not been investigated.
MATERIALS AND METHODS: Estrogen receptor alpha (ER alpha), ER beta, AIB1, and TIF2 protein expression were evaluated by immunohistochemistry in colorectal normal mucosa, adenomas, and adenocarcinomas from 110 patients with colorectal cancer.
RESULTS: ER alpha expression was rare in colorectal tissue and its expression does not appear to be associated with colorectal carcinogenesis. ER beta, AIB1, and TIF2 were detected in the nucleus of epithelial, endothelial, inflammatory, smooth muscle cells, and myofibroblasts. The expression of the three proteins was significantly increased in epithelial cells of carcinomas compared to normal mucosa. In carcinomas, a significant correlation between the levels of expression of AIB1 and TIF2 was noted. Although AIB1 overexpression was associated with local tumor invasion, it was also found to correlate independently with prolonged overall survival.
CONCLUSIONS: ER beta, AIB1, and TIF2 appear to be involved in colorectal tumorigenesis and might have prognostic significance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19198856     DOI: 10.1007/s00384-009-0647-9

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  70 in total

1.  Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway.

Authors:  C B Wade; S Robinson; R A Shapiro; D M Dorsa
Journal:  Endocrinology       Date:  2001-06       Impact factor: 4.736

2.  SRC-1 and TIF2 control energy balance between white and brown adipose tissues.

Authors:  Frédéric Picard; Martine Géhin; Jean- Sébastien Annicotte; Stéphane Rocchi; Marie-France Champy; Bert W O'Malley; Pierre Chambon; Johan Auwerx
Journal:  Cell       Date:  2002-12-27       Impact factor: 41.582

3.  Mice lacking the amplified in breast cancer 1/steroid receptor coactivator-3 are resistant to chemical carcinogen-induced mammary tumorigenesis.

Authors:  Shao-Qing Kuang; Lan Liao; Shu Wang; Daniel Medina; Bert W O'Malley; Jianming Xu
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

4.  Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice.

Authors:  Nancy L Cho; Sara H Javid; Adelaide M Carothers; Mark Redston; Monica M Bertagnolli
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

5.  Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer.

Authors:  J Kurebayashi; T Otsuki; H Kunisue; K Tanaka; S Yamamoto; H Sonoo
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

Review 6.  Mechanisms of estrogen action.

Authors:  S Nilsson; S Mäkelä; E Treuter; M Tujague; J Thomsen; G Andersson; E Enmark; K Pettersson; M Warner; J A Gustafsson
Journal:  Physiol Rev       Date:  2001-10       Impact factor: 37.312

Review 7.  Epigenetics and cancer.

Authors:  Anders H Lund; Maarten van Lohuizen
Journal:  Genes Dev       Date:  2004-10-01       Impact factor: 11.361

8.  Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation.

Authors:  P A Konstantinopoulos; A Kominea; G Vandoros; G P Sykiotis; P Andricopoulos; I Varakis; G Sotiropoulou-Bonikou; A G Papavassiliou
Journal:  Eur J Cancer       Date:  2003-06       Impact factor: 9.162

9.  Aberrant crypt foci in the adenoma prevention with celecoxib trial.

Authors:  Nancy L Cho; Mark Redston; Ann G Zauber; Adelaide M Carothers; Jason Hornick; Andrew Wilton; Stephen Sontag; Norman Nishioka; Francis M Giardiello; John R Saltzman; Chris Gostout; Craig J Eagle; Ernest T Hawk; Monica M Bertagnolli
Journal:  Cancer Prev Res (Phila)       Date:  2008-04-14

10.  Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells.

Authors:  Frank J Secreto; David G Monroe; Shamit Dutta; James N Ingle; Thomas C Spelsberg
Journal:  J Cell Biochem       Date:  2007-08-01       Impact factor: 4.429

View more
  13 in total

1.  Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis.

Authors:  Zinovia Kefalopoulou; Vassiliki Tzelepi; Vassiliki Zolota; Petros D Grivas; Christos Christopoulos; Haralabos Kalofonos; Theodoros Maraziotis; Georgia Sotiropoulou-Bonikou
Journal:  J Neurooncol       Date:  2011-07-07       Impact factor: 4.130

2.  Amplifications of NCOA3 gene in colorectal cancers in a Chinese population.

Authors:  Zhi Li; Zheng-Yu Fang; Yi Ding; Wan-Tong Yao; Yang Yang; Zhong-Qing Zhu; Wen Wang; Qin-Xian Zhang
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

3.  AIB1 as an independent prognostic marker in hepatocellular carcinoma after hepatic resection.

Authors:  Jun-Min Song; Min Lu; Fang-Fang Liu; Xiao-Juan Du; Bao-Cai Xing
Journal:  J Gastrointest Surg       Date:  2011-11-04       Impact factor: 3.452

Review 4.  New targets for the antitumor activity of gambogic acid in hematologic malignancies.

Authors:  Li-jing Yang; Yan Chen
Journal:  Acta Pharmacol Sin       Date:  2012-12-31       Impact factor: 6.150

5.  Common single-nucleotide polymorphisms in the estrogen receptor β promoter are associated with colorectal cancer survival in postmenopausal women.

Authors:  Michael N Passarelli; Amanda I Phipps; John D Potter; Karen W Makar; Anna E Coghill; Karen J Wernli; Emily White; Andrew T Chan; Carolyn M Hutter; Ulrike Peters; Polly A Newcomb
Journal:  Cancer Res       Date:  2012-11-13       Impact factor: 12.701

Review 6.  SRC-3 has a role in cancer other than as a nuclear receptor coactivator.

Authors:  Gang Ma; Yu Ren; Ke Wang; Jianjun He
Journal:  Int J Biol Sci       Date:  2011-05-24       Impact factor: 6.580

7.  Inhibition of ERβ induces resistance to cisplatin by enhancing Rad51-mediated DNA repair in human medulloblastoma cell lines.

Authors:  Anna Wilk; Agnieszka Waligorska; Piotr Waligorski; Augusto Ochoa; Krzysztof Reiss
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

8.  Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy.

Authors:  Kalpit Shah; Neil A Bradbury
Journal:  Oncotarget       Date:  2015-06-10

9.  Downregulation of steroid receptor coactivator-2 modulates estrogen-responsive genes and stimulates proliferation of mcf-7 breast cancer cells.

Authors:  Ingvild S Fenne; Thomas Helland; Marianne H Flågeng; Simon N Dankel; Gunnar Mellgren; Jørn V Sagen
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

10.  PELP1 suppression inhibits colorectal cancer through c-Src downregulation.

Authors:  Zhifeng Ning; Youzhi Zhang; Hanwei Chen; Jiliang Wu; Tieshan Song; Qian Wu; Fuxing Liu
Journal:  Oxid Med Cell Longev       Date:  2014-05-22       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.